Decatecholaminisation during sepsis

Crit Care. 2016 Oct 4;20(1):309. doi: 10.1186/s13054-016-1488-x.

Authors

Alain Rudiger¹, Mervyn Singer²

Affiliations

¹ Institute of Anaesthesiology, University Hospital Zurich, Raemistrasse 100, CH 8091, Zurich, Switzerland. alain.rudiger@usz.ch.
² Bloomsbury Institute of Intensive Care Medicine, University College London, London, WC1E 6BT, UK.

No abstract available

Publication types

Editorial

MeSH terms

Adrenergic alpha-2 Receptor Agonists / pharmacokinetics
Adrenergic alpha-2 Receptor Agonists / therapeutic use
Adrenergic alpha-Agonists / pharmacokinetics
Adrenergic alpha-Agonists / therapeutic use
Adrenergic beta-1 Receptor Antagonists / pharmacokinetics
Adrenergic beta-1 Receptor Antagonists / therapeutic use
Catecholamines / adverse effects*
Catecholamines / physiology*
Dexmedetomidine / pharmacokinetics
Dexmedetomidine / therapeutic use
Humans
Norepinephrine / pharmacokinetics
Norepinephrine / therapeutic use
Propanolamines / pharmacokinetics
Propanolamines / therapeutic use
Sepsis / drug therapy*
Sepsis / physiopathology*

Substances

Adrenergic alpha-2 Receptor Agonists
Adrenergic alpha-Agonists
Adrenergic beta-1 Receptor Antagonists
Catecholamines
Propanolamines
Dexmedetomidine
esmolol
Norepinephrine

Associated data

ClinicalTrials.gov/NCT01760967